Cargando…

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors

Vascular disrupting agents as DMXAA inhibit tumor growth only for a short period of time followed by rapid tumor regrowth. Among others, hypoxia and presence of transcription factor HIF-1α are responsible for tumors regrowth. The aim of our study was to investigate the inhibition of murine melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolarczyk, Ryszard, Cichoń, Tomasz, Pilny, Ewelina, Jarosz-Biej, Magdalena, Poczkaj, Aleksandra, Kułach, Natalia, Szala, Stanisław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943409/ https://www.ncbi.nlm.nih.gov/pubmed/29743548 http://dx.doi.org/10.1038/s41598-018-25688-y

Ejemplares similares

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
por: Drzyzga, Alina, et al.
Publicado: (2021)

Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma
por: Kułach, Natalia, et al.
Publicado: (2021)

Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2015)

Human ADSC xenograft through IL-6 secretion activates M2 macrophages responsible for the repair of damaged muscle tissue
por: Pilny, Ewelina, et al.
Publicado: (2019)

Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2019)

Monitoring of diffusion properties and transverse relaxation time of mouse ischaemic muscle after administration of human mesenchymal stromal cells derived from adipose tissue
por: Skorupa, Agnieszka, et al.
Publicado: (2019)

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
por: Czapla, Justyna, et al.
Publicado: (2023)

The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells
por: Czapla, Justyna, et al.
Publicado: (2019)

M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2018)

Brachytherapy in a Single Dose of 10Gy as an “in situ” Vaccination
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2020)

D-K(6)L(9) Peptide Combination with IL-12 Inhibits the Recurrence of Tumors in Mice
por: Cichoń, Tomasz, et al.
Publicado: (2014)

Characteristic of c-Kit(+) progenitor cells in explanted human hearts
por: Matuszczak, Sybilla, et al.
Publicado: (2014)

Antitumor Effects of Recombinant Antivascular Protein ABRaA-VEGF(121) Combined with IL-12 Gene Therapy
por: Ciomber, Agnieszka, et al.
Publicado: (2013)

Human Cardiac Mesenchymal Stromal Cells with CD105(+)CD34(-) Phenotype Enhance the Function of Post-Infarction Heart in Mice
por: Czapla, Justyna, et al.
Publicado: (2016)

The Effect of Radiotherapy on Cell Survival and Inflammatory Cytokine and Chemokine Secretion in a Co-Culture Model of Head and Neck Squamous Cell Carcinoma and Normal Cells
por: Matuszczak, Sybilla, et al.
Publicado: (2023)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
por: Roberts, Zachary J., et al.
Publicado: (2007)

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant
por: Tang, Choon Kit, et al.
Publicado: (2013)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

Inappropriate use of digoxin in patients presenting with digoxin toxicity
por: Tatlisu, Mustafa Adem, et al.
Publicado: (2015)

Effect of Heme Oxygenase-1 on Melanoma Development in Mice—Role of Tumor-Infiltrating Immune Cells
por: Was, Halina, et al.
Publicado: (2020)

Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning.
por: Brown, J. H., et al.
Publicado: (1986)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable?
por: Saad, Antonio F., et al.
Publicado: (2016)

Chronic Digoxin Toxicity: An Evaluation of Digoxin-Specific Antibodies and Other Management Options
por: Clifford, Liam M, et al.
Publicado: (2023)

Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
por: Gao, Pu, et al.
Publicado: (2014)

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
por: Weiss, Julia M., et al.
Publicado: (2017)

Serum digoxin concentrations in dogs with atrial fibrillation under long term digoxin treatment
por: Colella, Antonella, et al.
Publicado: (2022)

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

Pharmaco-Toxicological Assessment of the Combined Cytotoxic Effects of Digoxin and Betulinic Acid in Melanoma Cells
por: Rednic, Robert, et al.
Publicado: (2022)

Neglected facts in digoxin intoxication
por: Serin, Sibel Ocak
Publicado: (2017)

‘Digoxin conundrum – Time for validation?’
por: Yadava, O.P.
Publicado: (2021)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Pharmacokinetic Considerations for Digoxin in Older People
por: Currie, Geoffrey M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1jt7p9hnpraph7b3l0p41oin0q